Detection of Long Term Toxicity of Monoclonal Agents Combined With Chemotherapy in Non-Hodgkin Lymphoma - the SIMONAL Project
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 1,671
- 试验地点
- 1
- 主要终点
- Health problems
研究概览
简要总结
Non Hodgkin lymphoma (NHL) is the 5th cancer in France. Advances in NHL therapy have resulted in improved cure rates with a 5 year relative survival rate estimated at 55% and a 5-year prevalence estimate of 27,750 cases. Since 2000, the addition of anti-CD20 antibody to the standard treatment regimen composed of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) led for the first time to decline of the specific mortality.
After treatment, patients with NHL experienced elevated risks for therapy-related leukemia, several solid tumors and late toxicities such as cardiovascular or neuro-psychiatric diseases which impact on quality of life. However little is known concerning long-term toxicity of this class of new agents so called "targeted drugs" such as anti-CD20.
The primary objective of this cohort study is to estimate long term toxicity in NHL patients (i.e. 10 to 20 years) using data already collected (i.e. internal analysis) and to compare drugs consumption to that of controls (i.e. external analysis).
详细描述
The French public healthcare system perspective developed a unique SNIIR-AM (interregimens National Information Health Insurance system.) data base that contains up to 18 TeraOctet of medical consumption data (consultations, exams and drug prescriptions and hospitalization, yes/no). Its main limitation to detect disproportionate consumption after cancer care is the lack of data available on socio-demographic, pre-diagnostic patient and disease characteristics.
The LYSA (Lymphoma Study Association) is a national cooperative group which is world pioneer in NHL treatment with novel agents. Patient's bio clinical and demographic characteristics (n=10.000) are fully monitored and stocked in a data base registered in 2006 by the French National Cancer Institute (INCA). The cooperative network of 100 LYSA centre allows following all the patients on long term (up to 20 years after diagnosis).
Then, the mixture of these two sources of data will offer a unique material at the nation scale to detect signal of late onset disease, possibly linked to the initial cancer treatment.
Statistical Methods Disproportionate reporting of drugs consumption in fields of neuro-psychiatric troubles, cardio-vascular diseases, anti-cancer agents, antibiotics and antiviral agents will be extract from the French public healthcare database (external analysis). An economical study is embedded.
As the LYSA data contained all fully monitored patients' bio clinical and demographic characteristics, special attention will be paid to the addition of new agents, in particular anti-CD20 antibody, to the cytotoxic chemotherapy regimens in conjunction with other well-known risk factors (e.g. tobacco, obesity, comorbidities; internal analysis).
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 90 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Initial diagnosis of histologically confirmed CD20+ diffuse large B-cell Lymphoma, De novo transformed follicular lymphoma (FL) is allowed
- •Follicular lymphoma
- •Mantle cell lymphoma
- •Previously untreated with chemo- or radiotherapy
- •Include in LYSA trial
- •Age 18-90 years
排除标准
- •Any other type of lymphoma.
- •Previous treatment with chemotherapy or radiation therapy
- •Contraindication to any drug contained in the chemotherapy regimen
- •Previously known HIV positive serology
- •Active hepatitis B or C
- •Prior history of malignancies other than lymphoma within 3 years
结局指标
主要结局
Health problems
时间窗: Day 0
Disproportionate reporting of health problems in relation with neuro-psychiatric troubles, cardio-vascular diseases, digestive tract diseases etc.
health care use
时间窗: Day 0
Disproportionate reporting of health care use (drug consumption, hospitalization, doctors consultations)
次要结局
未报告次要终点